Abeona Therapeutics
ABEO
88 hedge funds and large institutions have $471M invested in Abeona Therapeutics in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 19 closing their positions.
95% more call options, than puts
Call options by funds: $6.19M | Put options by funds: $3.17M
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
6.83% more ownership
Funds ownership: 62.62% → 69.45% (+6.8%)
1% more capital invested
Capital invested by funds: $464M → $471M (+$6.24M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 93 → 88 (-5)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$13.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.4M |
| 4 |
Millennium Management
New York
|
+$11.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CHP
Castle Hook Partners
New York
|
-$18.9M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$12.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.42M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.17M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.65M |
ABEO Hedge Fund Activity: Q1 2018 in Review
88 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q1 2018, worth a combined $471M — up 1.3% from $464M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ABEO and 15 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 34 added.
The largest buyer was Citadel Advisors, adding an estimated $24.1M. The largest seller was Castle Hook Partners, exiting entirely with an estimated $18.9M sold.
- 88 institutional investors held Abeona Therapeutics (ABEO) as of Q1 2018, down from 93 in Q4 2017.
- Funds reported $471M of Abeona Therapeutics stock for Q1 2018, up 1.3% quarter-over-quarter.
- 15 funds opened new Abeona Therapeutics positions in Q1 2018 and 19 closed out, a net change of -4 holders.
- The largest Abeona Therapeutics buyer in Q1 2018 was Citadel Advisors, an estimated $24.1M added.
- The largest Abeona Therapeutics seller in Q1 2018 was Castle Hook Partners, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2018.